SCHEMBL21930331

SCHEMBL21930331

O=C(OC[C@@]1(CO)CCCc2cc(Cl)ccc21)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 2/20 0.42
▸ KDM4C Q9H3R0 1/20 0.40
▸ BACE1 P56817 1/20 0.39
▸ KDM1A O60341 1/20 0.38
▸ POLB P06746 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MCL1 Q07820 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ PRKCA P17252 1/20 0.36
▸ PRKCE Q02156 1/20 0.36
▸ RASGRP3 Q8IV61 1/20 0.36
▸ CHRNB2 P17787 1/20 0.36
▸ CHRNA5 P30532 1/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ CHRNA4 P43681 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21929993 1.00 SIGMAR1 (0.42) SIGMAR1KDM4CBACE1KDM1APOLB
SCHEMBL21930080 1.00 SIGMAR1 (0.42) SIGMAR1KDM4CBACE1KDM1APOLB
SCHEMBL17542334 0.89 KDM4C (0.39) SIGMAR1KDM4CBACE1KDM1APOLB
SCHEMBL17542336 0.89 KDM4C (0.39) SIGMAR1KDM4CBACE1KDM1APOLB
SCHEMBL26194439 0.89 RAB9A (0.39) SIGMAR1KDM4CKDM1APOLBMCL1
SCHEMBL26731609 0.87 SIGMAR1 (0.42) SIGMAR1L3MBTL1RAB9APRKCAPRKCE
SCHEMBL23442101 0.84 KDM1A (0.41) SIGMAR1KDM4CBACE1KDM1AMCL1
SCHEMBL17558380 0.83 ALDH1A1 (0.38) SIGMAR1KDM4CBACE1KDM1ARAB9A
SCHEMBL17558377 0.83 ALDH1A1 (0.38) SIGMAR1KDM4CBACE1KDM1ARAB9A
SCHEMBL21930213 0.82 SIGMAR1 (0.42) SIGMAR1KDM4CBACE1KDM1APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357275-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN PRELUDE THERAPEUTICS INCORPORATED 2023-11-09 — — US disclosed
US-20230357275-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN PRELUDE THERAPEUTICS INCORPORATED 2023-11-09 — — US disclosed
US-20230357275-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN PRELUDE THERAPEUTICS INCORPORATED 2023-11-09 — — US disclosed
EP-4149947-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN Prelude Therapeutics, Incorporated (US) 2023-03-22 — — EP disclosed
US-20230010358-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2023-01-12 — — US disclosed
US-20230010358-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2023-01-12 — — US disclosed
WO-2021231737-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-11-18 — — WO disclosed
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-09-28 — — US disclosed
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein PRELUDE THERAPEUTICS, INCORPORATED (US) 2021-09-28 — — US disclosed
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2020-05-14 — — US disclosed
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein PRELUDE THERAPEUTICS, INCORPORATED 2020-05-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130769-B2 Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein MCL1, BCL2A1, BCL2L1 SIGMAR1 2212/4885KDM4C 4355/4885BACE1 3911/4885
US-20230357275-A1 SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN MCL1, BCL2A1, BCL2L1 SIGMAR1 2199/4885KDM4C 4190/4885BACE1 3499/4885
US-20200148705-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein MCL1, BCL2A1, BCL2L1 SIGMAR1 2212/4885KDM4C 4355/4885BACE1 3911/4885
US-20230010358-A1 Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein MCL1, BCL2A1, BCL2L1 SIGMAR1 2212/4885KDM4C 4355/4885BACE1 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback